Privium Fund Management B.V. Grows Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Privium Fund Management B.V. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 23.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 357,502 shares of the biopharmaceutical company’s stock after buying an additional 67,698 shares during the quarter. Ultragenyx Pharmaceutical accounts for about 1.5% of Privium Fund Management B.V.’s investment portfolio, making the stock its 20th largest holding. Privium Fund Management B.V.’s holdings in Ultragenyx Pharmaceutical were worth $8,223,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,024 shares during the last quarter. Huntington National Bank boosted its stake in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares during the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $39,000. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,169 shares during the last quarter. Finally, Covestor Ltd boosted its stake in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RARE shares. HC Wainwright dropped their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. The Goldman Sachs Group lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and dropped their price target for the company from $61.00 to $25.00 in a research report on Tuesday, March 24th. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Sunday. Morgan Stanley upped their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. Finally, Truist Financial raised Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.76.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $25.01 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $42.37. The business’s fifty day moving average price is $22.55 and its two-hundred day moving average price is $26.90. The firm has a market capitalization of $2.46 billion, a PE ratio of -4.28 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.50) by ($0.34). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.38 million. During the same period in the prior year, the business earned ($1.57) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was down 2.2% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.49 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,683 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $24.90, for a total value of $116,606.70. Following the sale, the chief financial officer directly owned 110,342 shares of the company’s stock, valued at $2,747,515.80. This trade represents a 4.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Emil D. Kakkis sold 54,404 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares in the company, valued at $15,025,063.20. This represents a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 111,178 shares of company stock valued at $2,534,628 over the last three months. 5.20% of the stock is currently owned by company insiders.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Crysvita and Dojolvi product sales provide commercial ballast — Q1 product revenues included Crysvita $93M and Dojolvi $18M, showing underlying commercial traction even as total revenue declined. GlobeNewswire: Q1 Results
• Positive Sentiment: Some analysts remain bullish — a recent published price target of $61.18 signals continued upside expectations from parts of the street, which can support buying interest over the medium term. Analyst Price Target
• Neutral Sentiment: FY-2026 revenue guidance given as $730M–$760M (consensus ~$747M) — the range straddles Street expectations, so the top-line outlook is roughly in line with consensus but leaves EPS guidance unclear in public notes. This tempers but does not resolve near-term earnings concerns. Guidance in Press Release
• Neutral Sentiment: Large institutional holdings and recent stake increases from firms like Vanguard and State Street indicate continued institutional interest that may stabilize trading. MarketBeat: Institutional Holdings
• Negative Sentiment: Q1 EPS missed materially: reported loss per share $1.84 vs. consensus ≈ $1.50–$1.55; revenue fell ~2.2% YoY to $136M, underscoring near-term profitability and growth concerns. These misses are the primary negative driver. Zacks: Q1 Loss, Miss
• Negative Sentiment: Insider selling by the CFO (multiple recent sales, latest ~4,683 shares) may be viewed negatively by some investors as a signal of reduced insider conviction or portfolio diversification. SEC Filing: Insider Sale
• Negative Sentiment: Broader sell-side repositioning (e.g., past Goldman downgrade and mixed analyst actions) increases short-term volatility risk as investors digest the earnings gap and guidance nuance. MarketBeat: Analyst Notes

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.